Read the current Defeat Diabetes® E-Lerts™ Newsletter

This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

 
 
 
     
    
      
       
Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300

Madeira Beach, FL 33708
  

Diabetic Pancreatic Cancer Patients Live Longer with Diabetes Drug

Posted: Tuesday, April 17, 2012

About 80 percent of people diagnosed with pancreatic cancer also have diabetes.
 
While it's known that the two diseases are linked, the exact nature of this association remains unclear. What is clear is that the diabetes medication metformin may help folks living with pancreatic cancer. And that pancreatic cancer patients with diabetes who are prescribed metformin may live longer than those who are not given the common diabetes medication.

Donghui Li, Ph.D., a professor at The University of Texas MD Anderson Cancer Center, led a team of researchers evaluating the effect metformin had on the lifespan of pancreatic cancer patients with diabetes.

"This study suggests that metformin use in patients with diabetes was associated with improved pancreatic cancer survival, so we should certainly begin study of its supplemental use in pancreatic cancer treatment," said Donghui Li, Ph.D.

Looking at existing data, Li and colleagues conducted a retrospective study, observing 302 patients who had both diseases, including 117 who were prescribed metformin. After one year, 63.9 percent of the people taking metformin were alive, compared with 46.3 percent of patients who were not given the medication. At two years, 30.1 percent of the treated individuals were alive, compared with 15.4 percent who weren't prescribed the diabetes drug.

In looking at the lives of all individuals participating in the study, the median (in the middle) lifespan was 15.2 months for those who took metformin and 11.1 months for those who didn't take the drug.

These benefits were seen in all stages of pancreatic cancer, with the exception of metastatic disease that had spread to other sites in the body.

Metformin was likely battling insulin resistance that's common in both diseases, according to Li, who says these results warrant a randomized clinical trial to confirm these findings.

Source: http://www.diabetesincontrol.com/index.php?option=com_content&view=article&id=12614&catid=53&Itemid=8, Clinical Cancer Research, April 2012.

 
 
 
 
 
Join us on Facebook
 
 
 

Send your unopened, unexpired diabetes testing supplies to:

Defeat Diabetes Foundation
150 153rd Ave, Suite 300
Madeira Beach, FL 33708

 

DDF advertisement
 

 Friendly Banner
 


Friendly Banner
 
 
 
Analyze nutrition content by portion
DDF advertisement